Poseida Therapeutics, Inc. announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022. Mr. Warner has more than 15 years of biotech and pharmaceutical experience, most recently serving as Vice President, Gene Therapy and Rare Disease at Novartis, where he was responsible for building a division to commercialize multiple gene therapies overseeing three therapeutic areas.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | -5.14% | -4.48% | -17.56% |
14/05 | Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises | MT |
14/05 | Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.56% | 283M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy